



# Analysis of protein glycation using fluorescent phenylboronate gel electrophoresis

SUBJECT AREAS:  
DIAGNOSTIC MARKERS  
ELECTROPHORESIS  
GLYCOCONJUGATES  
PROTEOMIC ANALYSIS

Marta P. Pereira Morais<sup>1</sup>, Dominic Marshall<sup>1</sup>, Stephen E. Flower<sup>2</sup>, Christopher J. Caunt<sup>1</sup>, Tony D. James<sup>2</sup>, Robert J. Williams<sup>1</sup>, Nicholas R. Waterfield<sup>1</sup> & Jean M. H. van den Elsen<sup>1</sup>

<sup>1</sup>Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, U.K. <sup>2</sup>Department of Chemistry, University of Bath, Bath, BA2 7AY, U.K.

Received  
6 November 2012

Accepted  
4 February 2013

Published  
27 March 2013

Correspondence and requests for materials should be addressed to J.M.H.v.d.E. (bssjmhve@bath.ac.uk)

**Glycated proteins are important biomarkers for age-related disorders, however their analysis is challenging because of the complexity of the protein-carbohydrate adducts. Here we report a method that enables the detection and identification of individual glycated proteins in complex samples using fluorescent boronic acids in gel electrophoresis. Using this method we identified glycated proteins in human serum, insect hemolymph and mouse brain homogenates, confirming this technique as a powerful proteomics tool that can be used for the identification of potential disease biomarkers.**

Protein glycation, also known as non-enzymatic glycosylation, has been implicated in various disease states<sup>1,2</sup> and is therefore an important biomarker for ageing and age-related chronic diseases such as diabetes, cardiovascular diseases, autoimmune diseases, cancer, and Alzheimer's disease (AD)<sup>3–11</sup>. This process whereby reducing sugar molecules such as glucose react with the amino groups of lysine, arginine or N-terminal amino acid residues of proteins ultimately leads to the formation of complex and stable advanced glycation endproducts (AGEs). This modification affects the folding, function and stability of long-lived proteins. The analysis of these non-enzymatic protein-carbohydrate adducts is challenging because of their complexity and variability. A variety of analytical techniques are currently used to analyse the protein modifications resulting from glycation, each with their advantages and limitations. Boronate affinity chromatography (BAC)<sup>12</sup>, for instance, is based on the interaction between boronic acid and *cis*-diol-containing carbohydrates. It can detect various types of glycated proteins and has been widely used, in low-performance agarose gel-based as well as high-performance chromatography-based systems<sup>13</sup>. It has been used for example to differentiate the HbA<sub>1c</sub> isoform as a marker for diabetes and indicator for blood sugar control. With BAC all types of glycation modifications as well as *N*- and *O*-linked glycosylation in a sample are retained and the identification and analysis of individual glycated proteins requires further separation steps. BAC has been successfully used as a sample enrichment step prior to high-performance liquid chromatography (HPLC) and mass spectrometry (MS) analyses<sup>14</sup>. Even though MS<sup>15</sup> is an ideal technique to determine the identity of protein band in a gel, the limited availability of database information specific for glycation adducts hampers the identification of the modifications. In addition, MS only detects the most abundant proteins and if only a small percentage of a given protein species in a sample has suffered glycation damage, these adducts are likely to go undetected. Furthermore, any information regarding the specific glycation state can be lost after digestion of the protein samples prior to analysis.

In order to provide a simple, cost-effective detection and analysis tool for glycated proteins, we recently developed an electrophoresis based method using polyacrylamide incorporated with the carbohydrate affinity ligand methacrylamido phenylboronic acid (MPBA)<sup>16</sup>. We first tested this technique on simple carbohydrates and showed that by using the same basic principle as BAC, exploiting the reversible covalent interaction between boronic acid and *cis*-diols<sup>17,18</sup>, the MPBA-incorporated acrylamide gels enabled the improved separation of saccharides, and the differentiation between monosaccharides and disaccharides. Later we adapted this boronate-assisted saccharide electrophoresis (BASE) method to allow the separation of glycated from non-glycated proteins by incorporating MPBA into polyacrylamide gels for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) analysis<sup>19,20</sup>. This method, coined mP-AGE, showed that under electrophoresis conditions the polyacrylamide incorporated MPBA is specific for fructosamine modified proteins, via interactions with the *cis*-1,2-diol-containing fructosamine adducts and by further stabilisation through an electrostatic



interaction between the protonated amino group and the negatively charged boronate moiety<sup>19</sup>. This method enables the differentiation between early and late glycosylated adducts and has now been successfully used to analyse glycosylated human serum albumin (HSA) in serum from diabetes sufferers<sup>21</sup>.


Whilst mP-AGE aids the detection and separation of glycosylated proteins, it is only suitable for the analysis of samples with limited complexity. In this paper we present a novel application to detect and identify glycosylated proteins in a variety of complex protein samples, using fluorescent phenylboronic acid gel electrophoresis (Flu-PAGE) and Eastern blotting (Flu-BLOT).

## Results


Glycosylated proteins present in normal human serum can be visualised after incubation of serum with fluorophore-appended boronic acids in SDS-PAGE (Flu-PAGE) and Eastern blotting (Flu-BLOT) (Fig. 1). Incubation of normal human serum with fluorescein, fluorescein-boronic acid, rhodamine and rhodamine-boronic acid (Fig. 1A; structures of these compounds are shown in Supplementary Fig. S1) results in specific fluorescent staining of glycosylated HSA in SDS-PAGE, only in samples containing fluorescein- or rhodamine-appended boronic acid. No known glycosylated or non-glycosylated serum proteins are labelled using this method indicating that, similar to mP-AGE, the fluorescent boronic acids used in Flu-PAGE specifically interact with fructosamine modified proteins. Glycosylated

proteins labelled with both fluorophores show identical electrophoretic migration properties and can be readily transferred from the gels after electrophoresis (shown in Fig. 1A) to a polyvinylidene difluoride (PVDF) membrane and directly visualised with visible blue and UV light (Fig. 1B). This Flu-BLOT method can be used in conjunction with standard Western blotting methods, as shown in Fig. 1C. MALDI-TOF analysis of an additional fluorescent protein band in the rhodamine-boronic acid labelled human serum, observed in both Flu-PAGE and Flu-BLOT (Fig. 1A and 1B, lane 5', indicated by a white asterisk) was identified as *Apolipoprotein A-I* (ApoA-I).

To demonstrate that the Flu-PAGE method can be used to follow the glycosylation of human serum proteins over time, we subsequently incubated normal human serum with various reducing sugars, including glucose, fructose, mannose, maltose, and galactose. After 7 days of incubation with these sugars the HSA bands clearly show an increased fluorescence intensity in Flu-PAGE in the presence of fluorescein-boronic acid, especially in the sera that were incubated with glucose and mannose (Fig. 2). After 10 days of incubation, a significant increase in fluorescein-boronic acid labelling of HSA can be observed in the serum samples incubated with glucose, mannose and galactose, indicating increased levels of glycosylation by these sugars. A variety of other fluorescent protein bands can be observed, two of which were identified as *serotransferrin* and *Ig  $\gamma$  chain constant region*, using MALDI-TOF MS. These results are in agreement with the fluorescein-boronic acid labelling of sera from type I diabetes



**Figure 1 | Flu-PAGE and Flu-BLOT analyses of human serum.** Normal human serum (lanes 1, 1' and 1'') and serum samples labelled with fluorescein (lanes 2, 2' and 2''), fluorescein-boronic acid (lanes 3, 3' and 3''), rhodamine (lanes 4, 4' and 4'') and rhodamine-boronic acid (lanes 5, 5' and 5'') in a 12% non-denaturing polyacrylamide gel (A) and Eastern blot (B). The gels and blots were imaged with Dark Reader® (lanes 1–5), UV (365 nm, with orange filter (595 nm); lanes 1'–5') and UV (365 nm, with green filter (537 nm); lanes 1''–5''). The Coomassie stained control lane is shown in the left panel, labelled as C. The asterisks indicate an extra band present in the rhodamine-boronic acid labelled sample (lane 5') on both the Flu-PAGE and Flu-BLOT. (C) shows the Western blot analysis of glucose incubated HSA after 0 (lanes 1 and 2) and 28 days (lanes 3 and 4) using anti-AGE antibodies. Lanes 1 and 3 correspond to unlabelled samples, whereas lanes 2 and 4 are labelled with fluorescein-boronic acid.




**Figure 2 | Flu-PAGE analysis of *in vitro* glycated serum.** SDS-PAGE of human serum glycated with 50 mM sugar at 37°C for 7 and 10 days, lanes 2–7 and 8–12 respectively. Shown are non-incubated control (lane 1) and samples incubated with glucose (lanes 2 and 8), fructose (lanes 3 and 9), mannose (lanes 4 and 10), maltose (lanes 5 and 11), galactose (lanes 6 and 12), sucrose (lane 7). The left panel shows Coomassie stained gel (samples 1–12) and the right panel shows the gel visualised with UV prior to staining (lanes 1'–12'). The arrows indicate fluorescent proteins identified by MS.

patients (**Supplementary Fig. S3**), showing a clear increase in fluorescence intensity of HSA in two of the diabetic sera. One of the diabetic sera displays a level of HSA fluorescence that is comparable to control serum, however, this sample has a distinct additional fluorescent band at the 50 kDa position in the gel, indicative of IgG heavy chain glycation.

Next we tested the possible use of fluorescent boronic acid labelling of glycated proteins as a proteomics tool in 1) an insect model system that is currently in development as an animal model for diabetes (*Manduca sexta*) and 2) a murine model for AD.

Insects are becoming increasingly popular as protein glycation model systems and have been applied for identification of biomarkers in ageing in *Drosophila*<sup>22</sup>, and for testing anti-diabetic drugs in a hyperglycemic silk worm model<sup>23</sup>. Incubation of *Manduca sexta* hemolymph with fluorescein-boronic acid resulted in labelling of at least 10 different protein bands in Flu-PAGE (Fig. 3A). It is interesting to note that the majority of protein bands seen in the Coomassie stained gel are also labelled in the Flu-PAGE analysis, indicating that a large majority of the *Manduca sexta* hemolymph proteins are glycosylated. However, not all distinct fluorescent



**Figure 3 | Flu-PAGE analysis of *Manduca sexta* hemolymph.** (A) Flu-PAGE analysis of fifth instar *Manduca sexta* hemolymph. Lanes 1–3 are unlabelled hemolymph and lanes 4–6 are samples labelled with fluorescein-boronic acid. The left panel shows the Coomassie stained samples (lanes 1–6) whilst the right panel shows gel visualised with Dark Reader® prior to protein staining (lanes 1'–6'). The arrows indicate fluorescent bands analysed by MALDI-TOF and proteins identified using the *Manduca sexta* proteome database. *Inset*: comparison of Coomassie stained and Flu-PAGE stained section of the SDS-PAGE gel showing the differences in protein concentration and levels of glycation between three of the identified proteins. Indicated (white asterisk) is the position of Serpin 1, showing high levels of expression in hemolymph in the Coomassie stained gel and low levels of glycation with Flu-PAGE. (B) Flu-PAGE analysis of fluorescein-boronic acid labelled hemolymph taken from larvae at different developmental stages. Lanes 1–12 correspond to hemolymph extracted from larvae at 4, 6, 8, 10–18 days after hatching respectively. The left panel shows Coomassie stained gel (lanes 1–12) and the right panel shows visualisation using Dark Reader® prior to protein staining (lanes 1'–12'). *Inset*: glycation levels of some proteins vary dramatically during development. Phenoloxidase subunit 1A (indicated with white asterisk), a highly expressed protein in *Manduca sexta* hemolymph, shows low levels of glycation on days 16 and 17 and high levels of glycation on day 18, on advancement to pupa stage.



bands correspond to a high level of protein staining, signifying that some highly glycosylated proteins are present in low concentrations in the hemolymph samples. Conversely, some highly expressed proteins show low levels of glycosylation (as indicated in Figs. 3A and 3B, insets; see also Supplementary Fig. S4). Six protein bands, with approximate molecular weights: >200, 80, 45, 40 and 25 kDa were analysed by MALDI-TOF and identified using the *Manduca sexta* proteome database (Agricultural Pest Genomics Resource Database: www.agripestbase.org). The most prominent fluorescent protein band observed in the gels, indicating high levels of glycosylation, corresponds to *Apolipoprotein precursor protein* a lysine- and arginine-rich 367 kDa protein (see Supplementary Table S1) that constitutes the major component of lipophorin, which mediates transport for various types of lipids in hemolymph. Other glycosylated proteins identified in *Manduca sexta* hemolymph include: *phenoloxidase subunits 1 and 2*, two copper-containing oxidases (79 and 80 kDa, respectively) that function in the formation of pigments such as melanins and other polyphenolic compounds; *hemocyte aggregation inhibitor protein precursor* (48 kDa); *putative CIA cysteine protease precursor* (38 kDa) and *insecticyanin*, a 23 kDa protein synthesised in the caterpillar epidermis and secreted into the hemolymph.


We also used the Flu-PAGE to follow protein glycosylation during the development of the *Manduca sexta* caterpillar. The results in Fig. 3B show that whilst the levels of most hemolymph proteins remain constant during development, concentrations of proteins such as phenoloxidase vary dramatically and its expression appears to follow a wave pattern, peaking just before pupation. Glycosylation levels of the protein appear to be much lower at the beginning of an expression wave and much higher at the end of a wave, especially when expression levels peak before reaching pupation. A very striking example of this can be observed in the case of phenoloxidase subunit 1. Whilst a significant increase in the level of expression of this protein can be observed in the Coomassie stained gel on day 17 (Fig. 3B, lane 11), hardly any fluorescence is detected in the Flu-PAGE analysis. On day 18, just before entering pupation, the protein has clearly become

glycosylated as evidenced by the dramatic increase in fluorescence in the Flu-PAGE gel.

For the analysis of protein glycosylation in an AD mouse model, we used brain homogenates from transgenic mice that develop extensive amyloid  $\beta$  (A $\beta$ ) plaque pathology and normal controls. Brain homogenates were prepared from the cortices of 5-month-old heterozygote transgenic mice overexpressing both the hAPP695swe and the presenilin-1 M146V mutations (TASTPM<sup>24</sup>), and from age matched wild type C57BL/6 control animals. The results from the Flu-PAGE analysis of the brain samples are shown in Fig. 4 and Supplementary Fig. S5, where a UV image of the SDS-PAGE gel is compared with normal Coomassie stained gel. Although many bands are visible in the Coomassie stained gel, no other distinct fluorescent bands can be observed in the control cortex sample, with the exception of a strong band at approximately 120 kDa and a weaker low molecular weight band of about 15 kDa. In the TASTPM sample a large number of distinct fluorescent bands can be observed. Two groups of prominent bands can be seen between the 66 and 45 kDa molecular weight markers and between 35 and 25 kDa (Fig. 4). Five fluorescent bands between 35 and 25 kDa that are absent in the control mouse cortex sample were identified by MALDI-TOF analysis as 14-3-3 proteins ( $\epsilon$  and  $\zeta/\delta$ , with respective masses of 29 and 28 kDa), *triosephosphate isomerase* (27 kDa), *glutathione S-transferases Mu1* (26 kDa) and *P1* (23 kDa), respectively.

## Discussion

Glycosylated proteins are important biomarkers for age-related disorders, such as diabetes, cardiovascular diseases, autoimmune diseases, cancer, and AD. Biomarkers identifying biological and physiological entities associated with such diseases are becoming increasingly important for drug discovery. In this paper we show that glycosylated proteins can be visualised and identified in a variety of complex biological samples, including human serum, *Manduca sexta* hemolymph and mouse brain cortex homogenates, using fluorescent boronic acids in Flu-PAGE and Flu-BLOT.



**Figure 4** | Flu-PAGE analysis of TASTPM mouse cortex homogenates. Flu-PAGE gel profile of TASTPM cortex homogenates, visualised with Dark Reader<sup>®</sup> (right panel, lanes 2' and 3') prior to Coomassie staining (left panel, lanes 1–3). The solid arrows indicate the positions of the proteins that have been identified using MALDI-TOF analysis. The dotted arrows represent higher molecular weight fluorescent proteins to be investigated.



In samples of human serum, specific labelling of glycosylated HSA was observed in Flu-PAGE and Flu-BLOT and detection was most effective with fluorescein-boronic acid as it resulted in specific labelling of the glycosylated HSA band with all the wavelengths and filter combinations used (conventional visible blue light with 530 nm filter, and UV light sources with 595 and 537 nm filters). Glycosylated proteins labelled with rhodamine-boronic acid could be visualised best using UV with a 595 nm (orange) filter, however some aspecific labelling of HSA was observed in the rhodamine control lane. At this wavelength another glycosylated protein band was observed in the rhodamine-boronic acid labelled serum sample (Fig. 1A). The identified ApoA-I protein plays an important role in the transport of phospholipids and free cholesterol to the liver and its glycosylation has been linked to atherosclerosis and shown to contribute to its impaired action<sup>25</sup>. Analysis of human serum samples incubated with different reducing saccharides (Fig. 2), using Flu-PAGE, further identified serum proteins serotransferrin and IgG heavy chain as glycosylation targets. All of these high-abundance plasma proteins are well-known Amadori-modified proteins in type 2 diabetes and are linked with vascular complications<sup>26,27</sup>.

The Flu-PAGE results observed with saccharide-incubated serum samples are consistent with those found when analysing HSA glycosylation using mP-AGE<sup>19</sup>, showing strongest interactions between boronic acid and *cis*-1,2-diol-containing fructosamine adducts (resulting from glycosylation with glucose, mannose and galactose), stabilised by an electrostatic interaction between the protonated amino group and the negatively charged boronate moiety. When using Flu-PAGE in conjunction with mP-AGE analysis of the serum sample, the highest fluorescence intensity can be observed in the glycosylated HSA fraction that is retained in its electrophoretic mobility via interaction with the gel-incorporated MPBA (Supplementary Fig. S2).

Many proteins in *Manduca sexta* hemolymph appear to be affected by glycosylation in Flu-PAGE analysis. The most prominent fluorescent protein band corresponds to Apolipoprotein precursor protein, which has a function similar to Apo A-I, identified as a glycosylated protein in human serum (Fig. 1A), indicating that *Manduca sexta* could also be a useful model system for diseases such as atherosclerosis and AD. Some of the fluorescent bands in the hemolymph Flu-PAGE pattern do not correspond to clear Coomassie stained protein bands, implying that some highly glycosylated proteins are present in low concentrations. During the development of *Manduca sexta* the levels of most hemolymph proteins remain constant in all larval stages (Fig. 3B), however, concentrations of proteins such as phenoloxidase vary dramatically between larval stages and its expression appears to follow a wave pattern, peaking just before pupation. Our Flu-PAGE analysis shows that levels of protein glycosylation appear to be very low during the early stages of development and increase towards later stages. Interestingly, the fluorescein-boronic acid labelling of phenoloxidase also follows a wave-like pattern that is out of phase with its expression levels. The glycosylation of this protein appears to reach its peak in the days close to pupation. This corresponds with high hemolymph glucose levels at this stage of development (16 mM) when compared to feeding larvae (1 mM)<sup>28</sup>. This makes *Manduca sexta* an ideal model for following the effects of glycosylation during a hyperglycemic episode.

With this example we show that fluorescent boronic acid gel electrophoresis can be used to specifically identify glycosylated proteins in complex samples for normal development in non-disease states and in concert follow their temporal expression and glycosylation patterns. It should be noted that these insects are reared on a very high sugar diet, which may explain the overall high levels of glycosylation seen in their blood relative to the mammalian samples. Remarkably, there is a clear correlation between fluorescence intensity of the identified hemolymph proteins and the percentage of predicted glycosylated lysines in these proteins (Supplementary Fig. S4, also see Supplementary Table S1).

Similar to the *Manduca sexta* hemolymph samples, some of the distinct fluorescent bands seen in the Flu-PAGE analysis of TASTPM cortex homogenates do not show clear protein bands in the corresponding Coomassie stained gels, indicating that these proteins are present in low concentrations in the brain samples. MALDI-TOF analysis of the low molecular weight band (~15 kDa) present in both control and TASTPM homogenates identified this protein as hemoglobin, a well-known glycosylation marker in diabetes. Although the hemoglobin band is present in both control and TASTPM homogenates it appears brighter in the transgenic samples, indicating a higher level of glycosylation (Supplementary Fig. S5). The identified 14-3-3  $\epsilon$  and  $\zeta/\delta$  proteins have previously been linked with AD and shown to be present in the neurofibrillary tangles of AD brains<sup>29</sup>. It is interesting to note that of all the glycosylated proteins identified in this study, 14-3-3  $\zeta/\delta$  has the highest percentage of predicted glycosylated lysines (Supplementary Table S1). Both of the GST proteins, also discovered in the Flu-PAGE analysis of the TASTPM cortex homogenates, belong to a class of enzymes that function in the detoxification of hydrophobic electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins and products of oxidative stress, by conjugation with reduced glutathione. Glycosylation of these enzymes could affect their function and increase susceptibility to environmental toxins and carcinogens. Oxidative stress is strongly implicated in the pathology of AD and a recent study has shown that pro-oxidant conditions increase amyloidogenic processing of amyloid precursor protein (APP) and therefore might contribute to disease progression<sup>30</sup>.

In conclusion we show that fluorescent boronic acids can be used in gel electrophoresis and Eastern blotting for the detection and identification of individual glycosylated proteins in complex samples. The advantages of the Flu-PAGE and Flu-BLOT technology are summarised below:

- **Direct visualisation of glycosylated proteins.** Flu-PAGE and Flu-BLOT are the only methods that can directly visualise glycosylated proteins in SDS-PAGE and blots. This labelling method does not affect the electrophoretic migration properties of the proteins, nor does it hinder their subsequent identification by MS.
- **Detection of glycosylated proteins in complex samples.** This method is unique in that it detects glycosylated proteins in complex protein mixtures without the need of additional enrichment or purification techniques such as BAC. This method also enables the study of glycosylated proteins in the context of other non-affected proteins in fluid (human serum and insect hemolymph) and solid (mouse brain cortex homogenates) biosamples.
- **Detection for early glycosylation adducts.** The fluorescent boronic acids used in Flu-PAGE specifically interact with fructosamines, enabling the detection of early glycosylation adducts. With current methods to analyse glycosylated proteins using boronic acids (such as BAC) all types of glycosylation modifications in a sample are retained, including *N*- and *O*-linked glycans. Anti-AGE antibodies, used to detect glycosylated protein in western blotting methods, only recognise late stage glycosylation end products. Most of these antibodies lack specificity because they have been raised against a mixture of AGEs.
- **Flu-PAGE and Flu-Blot can be used in conjunction with other protein analysis tools.** We show in this paper that Flu-PAGE can be used in combination with an earlier developed method (mP-AGE) to label and separate glycosylated from non-glycosylated proteins. Flu-Blot can also be used in conjunction with antibody detection in western blots to enable multiple labelling of proteins.

Using a combination of Flu-PAGE and Flu-Blot we have *i*) identified differences in glycosylation between normal human serum and that of patients suffering from type 1 diabetes, *ii*) discovered novel glycosylated proteins in hemolymph from *Manduca sexta*, a new animal model system for diabetes, and *iii*) unveiled proteins that are affected by



glycation in an AD animal model. This easy-to-use method enables the study of protein glycation patterns in complex samples over time and in the context of development and disease. These results signify that fluorescent boronic acid gel electrophoresis (Flu-PAGE) and Eastern blotting (Flu-BLOT) provide a powerful and cost-effective first-stage proteomics tool for the identification and analysis of glycated protein biomarkers in ageing and age-related diseases and for probing novel glycation inhibitors and other anti-AGE therapies.

## Methods

**Human sera.** Human serum was obtained from Lonza, and serum albumin from Sigma-Aldrich. *In vitro* glycated human serum was obtained by incubating human serum with 50 mM glucose, fructose, mannose, maltose, galactose or sucrose (in the presence of 0.1% azide), in a dry heating block at 37°C for 7 or 10 days under aseptic conditions.

Type 1 diabetes human sera (from patients diagnosed using glutamic acid dehydrogenase (GAD) and insulin autoimmune antibodies (IAA and IA-2)) were obtained from SunnyLab UK.

**TASTPM mouse brain homogenates.** Cortex from heterozygote transgenic mouse over-expressing hAPP695swe and presenilin-1 M146V mutations (TASTPM) were obtained from GlaxoSmithKline, along with age-matched wild type C57BL/6, as previously reported<sup>24,30</sup>. All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals. The cortex samples were mechanically homogenised in 0.5 mL 50 mM Tris-EDTA buffer pH 7.4 with protease inhibitor (Roche), and spun at 2,000 g for five minutes to obtain crude homogenates.

**Manduca sexta hemolymph.** *Manduca sexta* larvae were kept individually on a wheat germ based artificial diet at 25°C with 17 h light: 7 h dark photoperiod. The larvae were chilled on ice for 30 minutes, and bled in sterile tubes after brief sterilisation with 70% ethanol and cutting the 'tail' near the tip. 5 µL of saturated phenoloxidase inhibitor 1-phenyl-2-thiourea (PTU, approx. 20 mM PTU in PBS) were added to 300 µL of hemolymph to prevent melanisation.

**Synthesis of fluorescent boronic acid compounds.** Fluorescein-boronic acid (3-(3-(3',6'-Dihydroxy-3-oxo-3 H-spiro[isobenzofuran-1,9'-xanthene]-5-yl)thioureido)phenylboronic acid, structure shown in **Supplementary Fig. S1A** right) was synthesised as previously reported<sup>31</sup>. Briefly, 3-aminobenzeneboronic acid (0.35 g, 2.57 mmol) was added to a solution of fluorescein isothiocyanate (1.00 g, 2.57 mmol) in DMF (5 mL), stirred at room temperature for 12 h then poured into methanol (10 mL). The solvents were removed *in vacuo* and residue re-dissolved in the minimum amount of fresh methanol. Chloroform was added and the product was obtained as a bright orange precipitate (920 mg, 68% yield).

Rhodamine-boronic acid (structure shown in **Supplementary Fig. S1B** right) was synthesised as follows. Triethylamine (3 eq. 0.56 mmol, 80 µL) was added to a solution of Rhodamine B isothiocyanate (100 mg, 0.18 mmol) and 3-aminobenzeneboronic acid (1.1 eq, 0.21 mmol, 28 mg) in dry DMF (5 mL) under N<sub>2</sub>. The reaction mixture was stirred overnight, then the solvent removed *in vacuo*. The reaction mixture was passed through a short pad of silica eluting with DCM, DCM/methanol (1% to 10%). The solvent was removed to give the product as a dark purple-red solid (65 mg, 58% yield).

**Labelling and electrophoresis of glycated proteins with fluorescent boronic acids.** 1 µL of 10-fold diluted human serum was incubated with 0.5 mM fluorescent boronic acid at room temperature for 1 h. Less stable samples can be labelled overnight at 4°C. Control samples were labelled with Fluorescein (Sigma-Aldrich; structure shown in **Supplementary Fig. S1A** left) or Rhodamine B (Sigma-Aldrich; structure shown in **Supplementary Fig. S1B** left).

Gel electrophoresis was performed using Xcell surelock mini-cell (Invitrogen) and Power Pac 300 (Bio-Rad). Proteins were blotted onto a 0.45 µm Immobilon-P PVDF membrane (Millipore) in transfer buffer (25 mM Tris, 192 mM glycine) at 15 V for 50 minutes, using a Trans blot SD Semi-dry transfer cell (Bio-Rad). The gels were visualised prior to protein staining with UV light (AlphaImager 3400 gel imaging system, Alpha Innotech; wavelength 365 nm, with orange (595 nm) or green (537 nm) filters) or Dark Reader<sup>®</sup> (Clare Chemicals Research Inc.; wavelength range 420–520 nm, with amber (~530 nm) filter). Contrast has been optimised for the gel and blot images.

After blotting, the membrane was blocked using TBST buffer (50 mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.6) with 5% milk powder at room temperature for 1 h. HRP-conjugated anti-AGE monoclonal antibody (1 : 800 dilution) was then applied to the blot at room temperature for 1 h. After five 30 min washes, the blot was incubated with peroxidase substrate for enhanced chemiluminescence (ECL, Pierce) at room temperature for 1 min before developing on film.

Monoclonal anti-AGE antibody (anti-AGE-BSA mAb clone 6D12, Cosmo Bio Co Ltd.) was provided by Dr Emmanuel Bourdon (Groupe d'Etude sur l'Inflammation Chronique et l'Obésité, Faculté des Sciences, La Réunion, France).

- Vlassara, H. Advanced glycation in health and disease: role of the modern environment. *Ann N Y Acad Sci* **1043**, 452–60 (2005).
- Vlassara, H. & Uribarri, J. Glycooxidation and diabetic complications: modern lessons and a warning? *Rev Endocr Metab Disord* **5**, 181–8 (2004).
- Kurien, B. T. & Scofield, R. H. Autoimmunity and oxidatively modified autoantigens. *Autoimmun Rev* **7**, 567–73 (2008).
- Wells-Knecht, M. C., Thorpe, S. R. & Baynes, J. W. Pathways of formation of glycooxidation products during glycation of collagen. *Biochemistry* **34**, 15134–41 (1995).
- Rahbar, S. Novel inhibitors of glycation and AGE formation. *Cell Biochem Biophys* **48**, 147–57 (2007).
- Unoki, H. & Yamagishi, S. Advanced glycation end products and insulin resistance. *Curr Pharm Des* **14**, 987–9 (2008).
- Vitek, M. P. *et al.* Advanced glycation end products contribute to amyloidosis in Alzheimer disease. *Proc Natl Acad Sci U S A* **91**, 4766–70 (1994).
- van Heijst, J. W., Niessen, H. W., Hoekman, K. & Schalkwijk, C. G. Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. *Ann N Y Acad Sci* **1043**, 725–33 (2005).
- Smith, M. A., Monnier, V. M., Sayre, L. M. & Perry, G. Amyloidosis, advanced glycation end products and Alzheimer disease. *Neuroreport* **6**, 1595–6 (1995).
- Smith, M. A., Sayre, L. M., Monnier, V. M. & Perry, G. Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. *Mol Chem Neurobiol* **28**, 41–8 (1996).
- Smith, M. A. *et al.* Advanced Maillard reaction end products are associated with Alzheimer disease pathology. *Proc Natl Acad Sci U S A* **91**, 5710–4 (1994).
- Klenk, D. C. *et al.* Determination of glycosylated hemoglobin by affinity chromatography: comparison with colorimetric and ion-exchange methods, and effects of common interferences. *Clin Chem* **28**, 2088–94 (1982).
- Zhang, Q., Ames, J. M., Smith, R. D., Baynes, J. W. & Metz, T. O. A Perspective on the Maillard Reaction and the Analysis of Protein Glycation by Mass Spectrometry: Probing the Pathogenesis of Chronic Disease. *Journal of Proteome Research* **8**, 754–769 (2008).
- Zhang, Q. *et al.* Enrichment and analysis of nonenzymatically glycated peptides: boronate affinity chromatography coupled with electron-transfer dissociation mass spectrometry. *J Proteome Res* **6**, 2323–30 (2007).
- Montgomery, H., Tanaka, K. & Belgacem, O. Glycation pattern of peptides condensed with maltose, lactose and glucose determined by ultraviolet matrix-assisted laser desorption/ionization tandem mass spectrometry. *Rapid Communications in Mass Spectrometry* **24**, 841–848 (2010).
- Jackson, T. R. *et al.* Boronate affinity saccharide electrophoresis: A novel carbohydrate analysis tool. *Electrophoresis* **29**, 4185–91 (2008).
- Fluckiger, R. & Gallop, P. M. Measurement of nonenzymatic protein glycosylation. *Methods Enzymol* **106**, 77–87 (1984).
- Gould, B. J. & Hall, P. M. m-Aminophenylboronate affinity ligands distinguish between nonenzymatically glycosylated proteins and glycoproteins. *Clin Chim Acta* **163**, 225–30 (1987).
- Pereira Morais, M. P. *et al.* Analysis of protein glycation using phenylboronate acrylamide gel electrophoresis. *Proteomics* **10**, 48–58 (2010).
- Pereira Morais, M. P., Fossey, J. S., James, T. D. & van den Elsen, J. M. Analysis of protein glycation using phenylboronate acrylamide gel electrophoresis. *Methods Mol Biol* **869**, 93–109 (2012).
- Guerin-Dubourg, A., Catan, A., Bourdon, E. & Rondeau, P. Structural modifications of human albumin in diabetes. *Diabetes Metab* **38**, 171–8 (2012).
- Jacobson, J. *et al.* Biomarkers of aging in *Drosophila*. *Aging Cell* **9**, 466–77 (2010).
- Matsumoto, Y., Sumiya, E., Sugita, T. & Sekimizu, K. An invertebrate hyperglycemic model for the identification of anti-diabetic drugs. *PLoS One* **6**, e18292 (2011).
- Howlett, D. R. *et al.* Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. *Brain Res* **1017**, 130–6 (2004).
- Park, K. H., Jang, W., Kim, K. Y., Kim, J. R. & Cho, K. H. Fructated apolipoprotein A-I showed severe structural modification and loss of beneficial functions in lipid-free and lipid-bound state with acceleration of atherosclerosis and senescence. *Biochem Biophys Res Commun* **392**, 295–300 (2010).
- Jaleel, A. *et al.* Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. *Diabetes Care* **28**, 645–52 (2005).
- Dolhofer, R. & Wieland, O. H. Increased glycosylation of serum albumin in diabetes mellitus. *Diabetes* **29**, 417–22 (1980).
- Siegert, K. J. Carbohydrate metabolism during the pupal molt of the tobacco hornworm, *Manduca sexta*. *Archives of Insect Biochemistry and Physiology* **28**, 63–78 (1995).
- Layfield, R. *et al.* Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. *Neurosci Lett* **209**, 57–60 (1996).
- Choudhry, F., Howlett, D. R., Richardson, J. C., Francis, P. T. & Williams, R. J. Pro-oxidant diet enhances beta/gamma secretase-mediated APP processing in APP/PS1 transgenic mice. *Neurobiol Aging* **33**, 960–968 (2012).



31. Elfeky, S. A. *et al.* Diol appended quenchers for fluorescein boronic acid. *Chem Asian J* **5**, 581–8 (2010).

*Manduca sexta* proteome database. C.J.C. contributed to the Eastern blot (Flu-Blot) development. M.P.P.M. and J.M.H.v.d.E. wrote the manuscript with editorial input from T.D.J., N.R.W. and R.J.W.

## Acknowledgments

We are indebted to Alzheimer's Research UK (ARUK-PPG2011B-17), Bath Ventures and the University of Bath Research Development & Support Office for funding. GlaxoSmithKline is thanked for providing the TASTPM brain samples.

## Author contributions

T.D.J. and J.M.H.v.d.E. conceived of the project. J.M.H.v.d.E. planned and supervised the project. M.P.P.M. conducted the experiments, with assistance from D.M. T.D.J. and S.E.F. designed, synthesised and analysed the fluorescent boronic acids. R.J.W. isolated the TASTPM brain tissues, prepared the homogenates and contributed to the analysis of the MS data. N.R.W. provided the *Manduca sexta* hemolymph and analysed the MS data using the

## Additional information

**Supplementary information** accompanies this paper at <http://www.nature.com/scientificreports>

**Competing financial interests:** The authors declare no competing financial interests.

**License:** This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>

**How to cite this article:** Pereira Morais, M.P. *et al.* Analysis of protein glycation using fluorescent phenylboronate gel electrophoresis. *Sci. Rep.* **3**, 1437; DOI:10.1038/srep01437 (2013).